Cabergoline Dosing for Ruminant Mammary Involution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiprolactin compounds used in veterinary medicine cannot be administered during gestation due to deleterious effects on the fetus, limiting their use in promoting mammary involution and reducing lactation in ruminants.
Innovation Solution
A veterinary composition comprising cabergoline, a dopamine receptor agonist, is administered in a single dose to ruminants during gestation to induce a significant drop in lactation and promote mammary involution without causing abortifacient effects, thereby improving udder health and reducing mastitis risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiprolactin compounds are administered to induce mammary involution and reduce lactation, then udder health and mammary involution are improved, but fetal safety deteriorates due to abortifacient effects during gestation
Solution Approach 1:
The patent changes the dosing parameters of cabergoline, administering it at low doses (0.01-0.1 mg/day) divided into multiple small doses throughout the day, rather than higher single doses. This parameter change allows the drug to effectively reduce prolactin and induce mammary involution while minimizing abortifacient effects on the fetus during gestation
Solution Approach 2:
The patent implements periodic administration of cabergoline in multiple small doses distributed throughout the day (e.g., 3-4 doses per day), rather than a single large dose. This periodic dosing strategy maintains therapeutic prolactin suppression while reducing peak plasma concentrations that could cause fetal harm, thus resolving the contradiction between udder health improvement and fetal safety
2Object-affected harmful factors
If antiprolactin compounds are avoided during gestation to ensure fetal safety, then fetal safety is maintained, but mammary involution and udder health deteriorate
Solution Approach 1:
The patent modifies the dosing parameters by using lower total daily doses (0.01-0.1 mg) administered in divided portions, which maintains effective prolactin suppression for mammary involution while staying below thresholds that cause fetal harm, thus enabling treatment during gestation
Solution Approach 2:
The patent employs periodic multiple small-dose administration throughout the day, which sustains therapeutic drug levels for mammary involution while avoiding dangerous peak concentrations that would threaten fetal safety, thereby resolving the contradiction
3Productivity
If a single high dose of antiprolactin compound is administered to quickly reduce lactation, then productivity improvement is achieved, but fetal safety and dosing precision deteriorate
Solution Approach 1:
The patent segments the total daily cabergoline dose into multiple smaller individual doses administered throughout the day (e.g., morning, noon, evening, and bedtime doses). This segmentation achieves sustained lactation reduction effectiveness while preventing the high peak concentrations that would cause fetal harm, thus resolving the contradiction between productivity improvement and fetal safety
Solution Approach 2:
The patent implements periodic administration of small doses at regular intervals throughout the day, which maintains consistent prolactin suppression for efficient lactation reduction while avoiding dangerous peak levels, thereby achieving both productivity improvement and fetal safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces lactation and promotes mammary involution in ruminants during gestation, improving udder health and reducing mastitis frequency without adverse effects on pregnancy or fetal development.
Implementation Method 1
cabergoline as a dopamine receptor agonist antiprolactinic compound
Implementation Method 2
inhibitors of pituitary secretion of prolactin, a hormone that activates milk secretion
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition contains at least one antiprolactinic compound that is an agonist of dopamine receptors, and is particularly useful for promoting a substantial reduction in lactation, mammary involution, and for treating and/or preventing diseases or infections of the udder of ruminants.